IthaID: 2500


Names and Sequences

Functionality: Globin gene causative mutation Pathogenicity: Benign / Likely Benign
Common Name: CD 47 GAC>CAC [Asp>His] HGVS Name: HBA1:c.142G>C
Hb Name: Hb Hasharon Protein Info: α1 47(CE5) Asp>His

Context nucleotide sequence:
CACCAAGACCTACTTCCCGCACTTC [G/C] ACCTGAGCCACGGCTCTGCCCAGGT (Strand: +)

Protein sequence:
MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFHLSHGSAQVKGHGKKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR

Also known as: Hb L-Ferrara, Hb Michigan-I, Hb Michigan-II, Hb Sealy, Hb Sinai

We follow the HGVS sequence variant nomenclature and IUPAC standards.

External Links

Phenotype

Hemoglobinopathy Group: Structural Haemoglobinopathy
Hemoglobinopathy Subgroup: α-chain variant
Allele Phenotype:N/A
Stability: Unstable
Oxygen Affinity: N/A
Associated Phenotypes: N/A

Location

Chromosome: 16
Locus: NG_000006.1
Locus Location: 37838
Size: 1 bp
Located at: α1
Specific Location: Exon 2

Other details

Type of Mutation: Point-Mutation(Substitution)
Effect on Gene/Protein Function: Missense codons (Protein Structure)
Ethnic Origin: Ashkenazi Jews, Brazilian, British
Molecular mechanism: N/A
Inheritance: Recessive
DNA Sequence Determined: Yes

HPLC

Disclaimer: The HPLC images are provided as an information resource only. Bio-Rad Laboratories, Inc and the ITHANET Portal disclaim responsibility and have no liability if this information is used for diagnostic or treatment purposes. D-10™ and VARIANT™ are registered trademarks of Bio-Rad Laboratories, Inc. and used with permission. Redistribution and use of the above material is allowed only with permission by Bio-Rad Laboratories, Inc. To access HPLC images and reports for different variants, use the IthaChrom tool.
ID Hb Variant Gene Instrument Method Area (%) Ret Time (min) Comments
429Hb Hasharonα1D-10Dual Kit Program29.14.56Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
425Hb Hasharonα1D-10Dual Kit Program25.44.56Heterozygote with alpha 3.7. Clinically normal in heterozygote. [PDF]
273Hb Hasharonα1D-10Dual Kit Program21.54.53heterozygote[PDF]
430Hb Hasharonα1VARIANTβ-thal Short Program27.94.74Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
426Hb Hasharonα1VARIANTβ-thal Short Program25.74.74Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
274Hb Hasharonα1VARIANTβ-thal Short Program19.54.74heterozygote[PDF]
432Hb Hasharonα1VARIANT IIDual Kit Program274.207Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
428Hb Hasharonα1VARIANT IIDual Kit Program25.94.205Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
427Hb Hasharonα1VARIANT IIβ-thal Short Program27.14.82Heterozygote with alpha 3.7. Clinically normal in heterozygote.[PDF]
276Hb Hasharonα1VARIANT IIDual Kit Program19.24.19heterozygote[PDF]
275Hb Hasharonα1VARIANT IIβ-thal Short Program204.82heterozygote[PDF]

In silico pathogenicity prediction

Publications / Origin

  1. Halbrecht I, Isaacs WA, Lehmann H, Ben-Porat F, Hemoglobin hasharon (alpha-47 aspartic acid--histidine)., Isr. J. Med. Sci. , 3(6), 827-31, 1967
  2. Ostertag W, Smith EW, Hb Sinai, a new alpha chain mutant alpha his 47., Humangenetik , 6(4), 377-9, 1968
  3. Schneider RG, Ueda S, Alperin JB, Brimhall B, Jones RT, Hemoglobin sealy (alpha 2-47His-beta 2): a new variant in a Jewish family., Am. J. Hum. Genet. , 20(2), 151-6, 1968
  4. Moradkhani K, Préhu C, Old J, Henderson S, Balamitsa V, Luo HY, Poon MC, Chui DH, Wajcman H, Patrinos GP, Mutations in the paralogous human alpha-globin genes yielding identical hemoglobin variants., Ann. Hematol. , 88(6), 535-43, 2009
Created on 2014-06-05 10:43:47, Last reviewed on 2022-04-20 13:02:38 (Show full history)

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaGenes are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.